CD38-targeted immuno-PET imaging to prevent myeloma relapse

This phase I/II proposal will assess the dose and safety of a combination of an antibody currently used for the treatment of multiple myeloma with a radiolabel element that will generate images on PET scan for disease detection and treatment response monitoring.

The central hypothesis is that targeted imaging of CD38, which is expressed on the surface of virtually every myeloma cell, will allow non-invasive immuno-PET imaging of myeloma in human patients. This would be a transformative, non-invasive strategy for the detection of myeloma and treatment response monitoring.